Evidence & regulatory context
- Mechanism
- Agonist c-Met antibody 5D5 with iPSC-derived hepatocyte transplantation; antibody + cell therapy.
- Target
- Not recorded
- Injury models
- Chemical/toxin
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- Not recorded
- ChEMBL record
- Not recorded
- ChEMBL max phase
- Not recorded
- Synonyms
- Not recorded
- Note
- Not recorded
Clinical trials 0
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
No linked human trial in this dataset.
Preclinical evidence 1
1 studies reported at therapy level; 1 evidence entries itemised.
MouseChemical/toxinFRGS (Fah, Rag2 and Il2rg deficient, immunodeficient)n = 20 mice per group in survival studiesIntraperitoneal injection of antibody; splenic injection of cells0.5 mg/kg weekly in vivo; 0.5 mg/mL in culture with escalat…Cell transplantation at day 7 after NTBC withdrawal with 5D5 from weeks 1 to 8…
Model: Three models: tyrosinaemic stress by NTBC withdrawal; acute liver failure by repeated intraperitoneal JO2 Fas/CD95 agonistic antibody every three days; chronic injury by carbon tetrachloride twice weekly for six weeks
Adding 5D5 to hepatocyte-like cell transplantation raised human liver chimerism to over 40 per cent and improved survival and liver function across the Fas, tyrosinaemic and carbon tetrachloride injury models without tumour formation.
Extraction: extract · Supplied extraction confidence: 0.85. Machine-extracted fields require source verification.